Pregabalin controlled-release - Ildong Pharmaceutical

Drug Profile

Pregabalin controlled-release - Ildong Pharmaceutical

Alternative Names: Pregabalin CR - Ildong Pharmaceutical; Pregabalin SR - Ildong Pharmaceutical

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Ildong Pharmaceutical
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jun 2013 Ildong Pharmaceutical completes a phase I trial in healthy volunteers in South Korea (NCT02103647)
  • 01 Jan 2013 Ildong Pharmaceutical completes a phase I trial in healthy volunteers in South Korea (NCT02103686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top